The global anti-infective agents market size was valued at USD 83.8 billion in 2015. The increasing prevalence of infectious diseases and the antimicrobial resistance to existing anti-infective agents are the drivers estimated to fuel the market growth. Moreover, the escalating base of health conscious individuals and the growing awareness levels, with regard to the availability of diagnostics for infectious diseases and the avoidable risks associated with early diagnosis are some of the factors projected to boost the growth of this industry.
Extensive R&D efforts pertaining to the development of new drugs with high efficacy and potency against multi-drug resistant micro-organisms is one of the major factors stimulating the growth of the global anti-infective agents market. New drug approvals are also estimated to accentuate the market growth over the forecast period. For instance, in 2016, the FDA approved drugs, such as Descovy by Gilead, for the treatment of HIV-1 infection and Zepatier by Merck that targets chronic HCV (Hepatitis C virus) genotypes 1 or 4 infection in adults.
U.S. anti-infective agent market, by type, 2014 - 2024 (USD Million)
Companies have recently launched a panel of FDA approved, modified antibiotics for their use in the treatment of acute bacterial skin and soft tissue infections; these drugs include Dalvance (Dalbavancin), Orbactive (Oritavancin), Sivextro (Tedizolid), and Zevtera (Ceftobiprole). The high market penetration of these anti-infective drugs due to their increased efficacy is expected to serve as a growth driver.
Commercialization of the anti-infective drugs in the pipeline is also estimated to be a key factor strengthening the market growth. In 2015, a recently introduced anti-fungal drug, Cresemba, marketed by Astellas Pharma US, Inc. gained FDA approval. The clinical trials revealed that the drug demonstrated significant efficacy in the treatment of patients with invasive mucormycosis and invasive aspergillosis.
The types of anti-infective agents comprise antibacterial, antifungal, and antiviral drugs. The anti-bacterial segment generated over USD 26.0 billion in 2015. The high revenue generation is attributed to the high prescription rates of these products and the broad spectrum activity of cephalosporin and penicillin.
The anti-fungal agents segment is further classified into azoles, echinocandins, and polyenes. Amongst these, Azoles are estimated to hold the largest market share owing to its high ability to combat systemic fungal infections.
However, the anti-viral agents segment is anticipated to exhibit a sharp increase in its growth in the coming decade owing to the introduction of novel drugs and the large patient population suffering from viral infections that require long treatment procedures. Furthermore, government collaborations with pharmaceutical companies for the development of new drugs are anticipated to support the growth of this sector. The market share of antivirals is estimated to grow to 45.0% in 2024.
North America was one of the dominated countries in 2015 with a revenue generation of over USD 26.3 billion. The presence of sophisticated healthcare infrastructure and high awareness amongst the end-users such as clinicians and healthcare professionals in this region are estimated to be the key factors contributing to this large share. Moreover, in this region, the high purchasing power of expensive drugs and the presence of favorablereimbursement policies are the drivers projected to accentuate the growth of the anti-infective agents market.
Asia-Pacific is expected to witness significant growth over the forecast period owing to the presence of generics companies, the rising economic stability, and the increasing level of disposable income. In addition, the growing geriatric population base coupled with the increased susceptibility to infections is expected to provide a potential growth platform to this industry.
Some of the key players of the anti-infective agents market are Pfizer Inc., Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc., Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and Novartis AG. Other prominent players include Astellas Pharma, Inc., GlaxoSmithKline Plc, Alcon Pharmaceuticals Ltd., Sanofi-Aventis S.A., and Johnson & Johnson.
Most of the companies are expanding their product portfolios by focusing on untapped oppurtunities. For instance, Gilead launched Sovaldi, the first-ever oral medication for the treatment of HCV genotype 2 and 3 in 2013.
The key players are also implementing certain competitive strategies such as mergers, acquisitions, and collaborations to dominate the market. In December 2015, Evotec AG and Spero Therapeutics announced the extension of their collaboration for the development of novel anti-bacterial drugs.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."